A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy

Biochemical Society Transactions

Volumn 42, Issue 4, 2014, Pages 831-836

  Claus, Jeroen ^a   Patel, Gargi ^b   Ng, Tony ^b   Parker, Peter J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Drug resistance; Epidermal growth factor receptor (EGFR); Human epidermal growth factor receptor 2 (HER2); Human epidermal growth factor receptor 3 (HER3); Kinase inhibition

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN;

CONFERENCE PAPER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; THERAPY RESISTANCE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84905863872     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140043     Document Type: Conference Paper

References (50)

1. Shi, F., Telesco, S.E., Liu, Y., Radhakrishnan, R. and Lemmon, M.A. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. U.S.A. 107, 7692-7697
2. Steinkamp, M.P., Low-Nam, S.T., Yang, S., Lidke, K.A., Lidke, D.S. and Wilson, B.S. (2014) ErbB3 is an active tyrosine kinase capable of homoand hetero-interactions. Mol. Cell. Biol. 34, 965-977
3. Peters, S., Adjei, A.A., Gridelli, C., Reck, M., Kerr, K. and Felip, E. (2012) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii56-vii64
4. Seufferlein, T., Bachet, J.B., Van Cutsem, E. and Rougier, P. (2012) Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii33-vii40
5. Gregoire, V., Lefebvre, J.L., Licitra, L. and Felip, E. (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v184-v186
6. Van Cutsem, E., Nordlinger, B. and Cervantes, A. (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann. Oncol. 21 (Suppl. 5), v93-v97
7. Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S. and Senkus, E. (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii11-vii19
8. Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A. and Arnold, D. (2013) Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 (Suppl. 6), vi57-vi63
9. Zhang, X., Gureasko, J., Shen, K., Cole, P.A. and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149
10. Jaiswal, B.S., Kljavin, N.M., Stawiski, E.W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K.A. et al. (2013) Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603-617
11. Collier, T.S., Diraviyam, K., Monsey, J. and Shen, W. (2013) Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J. Biol. Chem. 288, 25254-25264
12. Zimmermann, M., Zouhair, A., Azria, D. and Ozsahin, M. (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat. Oncol. 1, 11
13. Li, S., Schmitz, K.R., Jeffrey, P.D., Wiltzius, J.J. W., Kussie, P. and Ferguson, K.M. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7, 301-311
14. Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M. et al. (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86
15. Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Cora, D., Di Nicolantonio, F., Buscarino, M., Petti, C. et al. (2011) A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523
16. Takezawa, K., Pirazzoli, V., Arcila, M.E., Nebhan, C.A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y.Y., Spitzler, P.J., Melnick, M.A. et al. (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2, 922-933
17. Yun, C.-H., Boggon, T.J., Li, Y., Woo, M.S., Greulich, H., Meyerson, M. and Eck, M.J. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217-227
18. Boxer, S.G. and Levinson, N.M. (2013) a conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity. Nat. Chem. Biol. 10, 127-132
19. Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A., Koutcher, J.A., Spassova, M., Ouerfelli, O., Mellinghoff, I.K. et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000-3010
20. Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A.B., Chirieac, L., Iacob, R.E., Padera, R. et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074
21. Jura, N., Shan, Y., Cao, X., Shaw, D.E. and Kuriyan, J. (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. U.S.A. 106, 21608-21613
22. Sergina, N.V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K.M. and Moasser, M.M. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441
23. Amin, D.N., Sergina, N.V., Lim, L., Goga, A. and Moasser, M.M. (2012) HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem. J. 447, 417-425
24. Amin, D.N., Sergina, N.V., Ahuja, D., McMahon, M., Blair, J.A., Wang, D., Hann, B., Koch, K.M., Shokat, K.M. and Moasser, M.M. (2010) Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2, 16ra7
25. Xia, W., Petricoin, 3rd, E.F., Zhao, S., Liu, L., Osada, T., Cheng, Q., Wulfkuhle, J.D., Gwin, W.R., Yang, X., Gallagher, R.I. et al. (2013) An heregulin-EGFR-HER3 autocrine signaling axiscan mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res. 15, R85
26. Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R.M., Fu, X., Botero, M.F., Healy, N.A., Hilsenbeck, S.G., Phillips, G.L. et al. (2011) Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers: role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 13, R121
27. Narayan, M., Wilken, J.A., Harris, L.N., Baron, A.T., Kimbler, K.D. and Maihle, N.J. (2009) Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res. 69, 2191-2194
28. Ritter, C.A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J.A. and Arteaga, C.L. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13, 4909-4919
29. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.M., Zhao, X., Christensen, J. et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043
30. Shattuck, D.L., Miller, J.K., Carraway, K.L. and Sweeney, C. (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-1477
31. Rexer, B.N., Ghosh, R., Narasanna, A., Estrada, M.V., Chakrabarty, A., Song, Y., Engelman, J.A. and Arteaga, C.L. (2013) Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin. Cancer Res. 19, 5390-5401
32. Schoeberl, B., Pace, E.A., Fitzgerald, J.B., Harms, B.D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R. et al. (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2, ra31
33. Schoeberl, B., Faber, A.C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L. et al. (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70, 2485-2494
34. Zhou, B.-B.S., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N. et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39-50
35. Wilson, T.R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J. et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509
36. Schoeberl, B., Faber, A.C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L. et al. (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70, 2485-2494
37. Garner, A.P., Bialucha, C.U., Sprague, E.R., Garrett, J.T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C.R., Chen, D. et al. (2013) An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 73, 6024-6035
38. Schaefer, G., Haber, L., Crocker, L.M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C.V., Stawicki, S. et al. (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472-486
39. Huang, S., Li, C., Armstrong, E.A., Peet, C.R., Saker, J., Amler, L.C., Sliwkowski, M.X. and Harari, P.M. (2013) Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73, 824-833
40. McDonagh, C.F., Huhalov, A., Harms, B.D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S. et al. (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 11, 582-593
41. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
42. Kim, H.-P., Han, S.-W., Song, S.-H., Jeong, E.-G., Lee, M.-Y., Hwang, D., Im, S.-A., Bang, Y.-J. and Kim, T.-Y. (2013) Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene 33, 3334-3341
43. Gjerdrum, C., Tiron, C., Hoiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B.T. et al. (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. U.S.A. 107, 1124-1129
44. Holland, S.J., Pan, A., Franci, C., Hu, Y., Chang, B., Li, W., Duan, M., Torneros, A., Yu, J., Heckrodt, T.J. et al. (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 1544-1554
45. Zhang, Y.X., Knyazev, P.G., Cheburkin, Y.V., Sharma, K., Knyazev, Y.P., Orfi, L., Szabadkai, I., Daub, H., Keri, G. and Ullrich, A. (2008) AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 68, 1905-1915
46. Byers, L.A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P.K. et al. (2013) An epithelial- mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290
47. Zhang, Z., Lee, J.C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A.D., Rho, J.K. et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852-860
48. Giles, K.M., Kalinowski, F.C., Candy, P.A., Epis, M.R., Zhang, P.M., Redfern, A.D., Stuart, L.M., Goodall, G.J. and Leedman, P.J. (2013) Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther. 12, 2541-2558
49. Rho, J.K., Choi, Y.J., Kim, S.Y., Kim, T.W., Choi, E.K., Yoon, S.J., Park, B.M., Park, E., Bae, J.H., Choi, C.M. et al. (2014) MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 74, 253-262
50. Claus, J., Cameron, A.J.M. and Parker, P.J. (2013) Pseudokinase drug intervention: a potentially poisoned chalice. Biochem. Soc. Trans. 41, 1083-1088